Total Voting Rights
30 December 2022
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Total Voting Rights
Advanced Oncotherapy (AIM:AVO), the developer of LIGHT, the next-generation proton therapy system for cancer treatment, announces that the Company's issued share capital as at the date of this announcement comprises 537,481,209 ordinary shares of 25p each, with one voting right per share ("Ordinary Shares"). The Company does not hold any ordinary shares in treasury and therefore the total number of Ordinary Shares with voting rights in the Company is 537,481,209. This announcement is required to be made at month endin accordance with the FCA's Disclosure Guidance and Transparency Rules.
|
Advanced Oncotherapy plc |
|
|
Dr. Michael Sinclair, Executive Chairman |
Tel: +44 (0) 20 3617 8728 |
|
Nicolas Serandour, CEO |
|
|
|
|
|
Allenby Capital Limited (Nomad and Joint Broker) |
|
|
Nick Athanas / Piers Shimwell (Corporate Finance) Amrit Nahal / Matt Butlin (Sales and Corporate Broking) |
Tel: +44 (0) 20 3328 5656 |
|
|
|
|
SI Capital Ltd (Joint Broker) |
|
|
Nick Emerson |
Tel: +44 (0) 1483 413 500 |
|
Jon Levinson |
Tel: +44 (0) 20 3871 4066 |
|
|
|
|
|
|
|
|
|
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 8 minutes ago Urban Logistics Reit
- 20 minutes ago Ocado Group
- 32 minutes ago AJ Bell
- 44 minutes ago Foresight Enterprise VCT
- 53 minutes ago Mitie Group